Wednesday, 12 Dec 2018

You are here

Sons of Gout Study

The genetics and heritability of gout has suggested a higher risk in certain families.  A UK cohort study examined the prevalence of gout and monosodium urate (MSU) crystal deposition among those at risk (sons of gout patients) for gout and found a high incidence of hyperuricemia and MSU crystal deposition.

The sons of patients with gout (n=131) were contacted, screened by telephone and subsequently had a study-visit evaluation for blood and urine collection, and musculoskeletal ultrasonography (MSK US).

Amongst 131 sons of gout, 64.1% had serum urate (SU) ≥6 mg/dl, and 30% had MSK US evidence of either a double contour sign (DCS) or intra-articular aggregates/tophi in ≥1 joint.

All subjects with MSU deposition had involvement of 1st metatarsophalangeal joint and a subset (21%) had intra-tendinous aggregates.

For those with SU ≤5 mg/dl no MSU depositoin was found; but those 24% of those with SU between 5-6 mg/dl had ultrasonographic MSU deposition.

For every SU increased of 1 mg/dl, there was a 61% increase in the odds of finding MSU crystal deposition.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hepatic Safety of Urate Lowering Therapies in Gout

Lee and a group of Korean investigators have analyzed the comparative safety of allopurinol and febuxostat in a small cohort of gout patients with fatty liver disease (FLD) and found febuxostat had a lower risk for hepatotoxicity (defined as AST or ALT at least 3× the upper limit of normal) compared to allopurinol.

Treat-to-Target Strategy Cuts Mortality in Gout Patients

More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.

TRIPLE Trial Results

Pegloticase has become an excellent option for management of patients with chronic refractory gout, although treatment may be limited by the development of anti-drug antibodies that lead to loss of serum urate (sUA) lowering effect.

Gout and the Social Determinants of Health

During a fascinating gout session on October 21, Hyon Choi presented an important paper (abstract 874) which used data from the Health Professionals Follow-up Study to try to understand the rapid increase in the incidence of gout in recent decades.

Nurse Led Gout Management Highly Effective

UK researchers have shown that nurse-led gout management, using a treat-to-target urate-lowering strategy, is efficacious and cost-effective compared with usual physicain care. The results are published in the recent Lancet edition.

Worldwide, gout management is suboptimal. In the UK only 40% of gout patients receive urate-lowering therapy, and fewer ever achieve a target serum urate (< 6mg/d) concentration.